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In April 2008, the US Food and Drug Administration (FDA) published 
its controversial decision to abandon the Declaration of Helsinki (DoH) 
as an ethical guideline when conducting, and reviewing data from, 
clinical trials performed outside the USA. As early as 2006, the FDA 
declared it would eliminate all reference to the 2000 and subsequent 
revisions of the DoH. While it stipulated that it would continue to 
recognise the 1989 revision, this revision is considered invalid by the 
World Medical Association (WMA), the authors of the DoH.1 
Accordingly, the FDA now considers it sufficient that a trial performed 
outside USA soil adhere to the Good Clinical Practices of the 
International Conference of Harmonization (ICH-GCP). The reasons 
for this decision include the need to protect human subjects and to 
assure the quality and integrity of foreign data obtained from studies 
performed outside the USA.2 
Discussion
The DoH has been considered the benchmark of ethical and medical 
standards in clinical trials worldwide, even though it is not a legally 
binding document in international law. It has its origins in the Nuremberg 
Code (1947), and was developed in 1964. Its author, the WMA, includes 
85 national medical societies from around the world, compared with the 
ICH which consists only of voting members from the USA, the European 
Union, and Japan.3 In October 2008, the WMA General Assembly, 
meeting in Seoul, South Korea, voted to adopt the latest revision of the 
DoH after an 18-month revision process.4 The WMA considers the 2008 
DoH the only official revision, and regards it not just as an internal policy 
but as a universal statement of medical research ethics.4 
The 2008 revision of the DoH5 is more ethically demanding than the 
ICH-GCP, and addresses moral issues that the ICH-GCP guidelines do 
not.6 These include the restriction of placebo controls in clinical trials 
in developing countries; the disclosure of the trial design to the public; 
a requirement that the population in which the research is conducted 
should benefit from it, particularly in developing countries, and that 
participants should have post-trial access to treatment; the need 
to publish results; and the disclosure of conflicts of interest.3 There 
are concerns that the FDA’s abandonment of the DoH may cause 
other regulators to follow suit, with serious implications for ethical 
standards and participant safety in Third-world countries.
Research ethics in South Africa
In 2001, the World Health Organization Regional Committee for Africa 
expressed its concern that some health-related trials undertaken 
in developing African countries were not subjected to any form of 
ethics review.7 Some of the reasons quoted for conducting research 
in Africa, rather than in developed countries such as the USA or 
Europe, include lower costs, lower risk of litigation and less stringent 
ethical review.7 Concerns have also been raised that research ethics 
committees (RECs) in developing countries may not promote high 
standards of protection for research participants, due to a lack of 
financial and adequately trained human resources.7 
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However, a 2010 comparison between the US Common Rule and 
South African research ethics requirements by Cleaton-Jones and 
Wassenaar8 revealed that, at a structural level, the research ethics 
review process in South Africa is in many cases equivalent to the 
US institutional review board (IRB) and Office of Human Research 
Protections (OHRP) oversight system. In fact, it would appear to 
be stricter as it makes no exclusions, compared with the many 
exemptions allowed in ethics review and waivers of participant-
informed consent in the USA system.8 
Although strict guidelines and regulations per se will not prevent 
sub-standard ethical review, the FDA’s renouncement of the DoH 
may have long-term practical implications, and could encourage 
pharmaceutical companies to take ethical short cuts in developing 
and emerging countries. 
The use of placebos versus standard 
therapy
The clinical research testing of new strategies for the prevention 
and treatment of epidemics, such as HIV/AIDS, has become a critical 
necessity.9 However, developing countries, which stand to benefit 
the most from such research, lack the resources to conduct their 
own clinical trials.9 Many have a limited healthcare infrastructure and 
citizens may not have access to basic medical services. 
Article 32 of the DoH provides for the limited use of placebo arms 
in clinical trials. While a new test drug should be compared with the 
available golden standard of treatment or therapy instead of a placebo, 
placebo-controlled trials are allowed where no standard therapy exists, 
or ‘where for compelling and scientifically sound methodological 
reasons the use of placebo is necessary to determine the efficacy or 
safety of an intervention and the patients who receive placebo or no 
treatment will not be subject to any risk of serious or irreversible harm’.5
The debate over the application of research ethics and the use of 
placebo-controlled trials in developing countries surfaced in the 
early 1990s, in trials concerning the early prevention of mother-
to-child-transmission (MTCT) of HIV.10 In 1994, while there was 
an existing protocol from the AIDS Clinical Trial Group 076 (ACTG 
076) for preventing MTCT, high antiretroviral (ARV) costs and 
insufficient infrastructure placed it out of reach of most of the HIV-
infected population in the developing world.10 Due to an almost 
70% reduction in the risk of HIV transmission in the ACTG 076 trial, 
zidovudine became the de facto standard of care.11 To find a more 
cost-effective and applicable treatment for resource-poor settings, 
randomised placebo-controlled trials were initiated to investigate a 
short-course ARV regimen.10 
However, these trials sparked intense debate. On the one hand, 
they were viewed as exploitative as they violated the condition of 
equipoise, namely that placebo groups are only deemed ethical if the 
merit of the intervention is sufficiently uncertain. On the other hand, 
the responsiveness of the research was stressed. In fact, without these 
short placebo-based trials, countries such as South Africa would 
not have developed a low-cost intervention to prevent MTCT. The 
subsequent initiation of these trials in developing countries, funded 
by the US Center for Disease Control (CDC) and National Institutes of 
Health (NIH), raised further concern when it was learned that patients 
in trials in the USA had unrestricted access to the drug.11 
The arguments for not providing the ‘gold standard’ treatment 
available in developed countries were founded on the low standard 
of care in developing countries,10 and the fact that pregnant women 
in these countries did not access care early enough and were unlikely 
to cease breastfeeding. The NIH and CDC defended the trials’ design 
and, despite early opposition, the trials began in 16 countries 
and included over 12 000 HIV-infected women.10 These trials also 
appeared to be in direct conflict with guidelines for international 
research published by the Council for International Organizations of 
Medical Sciences (1993, Guideline 11), which stated that the ethical 
standards should be applied no less exactingly than they would be in 
the sponsoring or initiating country.11,12 
In addition to various international regulatory requirements, clinical 
trial investigators and pharmaceutical companies in South Africa 
need to adhere to the South African Good Clinical Practice (SAGCP) 
guideline, published by the Department of Health in 2000 and 
revised in 2006.13 Section 1.4 states that ‘Regulations established in 
terms of section 90(s) [health research] of the National Health Act 
(Act No. 61 of 2003)14 enforces these guidelines. Compliance with 
these guidelines is compulsory under the direction of the Director-
General of Health’.13 
Alongside other international guidelines, the SAGCP is based on the 
ICH-GCP as well as DoH (2004) (Section 1.3 of the SAGCP).13 Thus, the 
National Health Act indirectly enforces compliance with the ICH-GCP 
as well as the DoH for clinical trials conducted in SA.13 The SAGCP 
states that the use of placebos should be justified, and only when 
there is no known effective treatment should it be considered ethical 
to compare a potential new treatment with a placebo.13 
However, taking into account the 2004 DoH’s statements on the 
use of placebo-controlled trials, it seems that placebo control 
is more flexible. Given the already flexible grounds for placebo-
controlled trials based on scientific justification and compelling 
methodology, it would seem unlikely that the FDA’s decision 
would significantly affect South Africa. However, other developing 
countries could risk having their guidelines relaxed to allow these 
trials. This particularly affects emerging countries which lack 
standard therapies and the resources to conduct their own clinical 
trials. Given that pharmaceutical companies can already argue that 
emerging countries usually lack their own standard treatments, this 
could put an even greater burden on the future ethical rights and 
safety of trial participants.
Post-trial access to treatment and other trial 
benefits
Articles 14 and 33 of the DoH state that the clinical trial protocol 
should contain a statement of the ethical considerations involved, 
and should indicate how the DoH’s principles have been addressed.5 
It should also describe arrangement for participants’ post-trial access 
to appropriate care or benefits resulting from the trial.5 
However, this requirement is absent from the ICH-GCP. SAGCP 
stipulates that specific recommendations should be made for 
the continuation of treatments beyond after the trial, especially 
in research requiring additional attention, such as HIV research 
involving vulnerable communities.13 In developing countries without 
such an additional guarantee, this issue could become problematic.
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Since the FDA renounced the DoH, some pharmaceutical companies 
are choosing to omit any reference to the DoH when drafting 
protocols for trial conduct in South Africa or any other developing 
country. These companies can also test their new drugs in developing 
or emerging countries without planning to register them there, and 
with no obligation to provide participants with post-trial access to 
any treatment or other benefits.
Trial registration and publication of results
Article 19 of the DoH requires that all clinical trials be registered in a 
publicly accessible database before the first participant is recruited.5 
Likewise, the WHO considers trial registration a scientific, ethical and 
moral responsibility.9 
In early 2009, the HIV/AIDS, Tuberculosis and Malaria (ATM) Clinical 
Trials Registry became the principal registry for all clinical trials 
conducted in Africa.9 Recently renamed the Pan African Clinical Trials 
Registry (PACTR), it is part of a growing trend of compliance with the 
DoH and increasing local oversight of international medical research.9 
In the past several years some countries, including the USA, have 
established mandatory clinical trial registries.9 
As well as revealing the trial design, Article 30 of the 2008 DoH 
states that authors and sponsors have an ethical obligation to the 
public to publish research conducted on human participants,5 
including negative, inconclusive and positive outcomes. A 
significant proportion of medical research remains unpublished, 
or may be published with some results omitted.9 Selective 
reporting leads to an incomplete and potentially biased view of 
a trial and its results.9 
A lot of money, time and resources have been spent on compliance 
with the DoH. For countries such as SA, which already have 
guidelines for trial registration and results publication, the FDA’s 
decision might not be as significant. Yet for developing countries 
without these guidelines, this could hamper the current and future 
efforts of trial registries, and have financial implications for efforts 
already invested.
Conflicts of interest
Article 14 of the 2008 DoH states that the clinical trial protocol 
should contain a statement of the ethical considerations involved 
and indicate how the DoH’s principles have been addressed. It 
should also provide information on funding, sponsors, institutional 
affiliations, and other potential conflicts of interest to both RECs and 
trial participants.5 However, this principle is not specified in ICH-
GCP. This raises another ongoing ethical issue, since in 2012 the FDA 
announced that it might relax certain conflict-of-interest restrictions 
that prevent scientists with financial ties to the drug industry from 
becoming members of its advisory panels15 (the FDA appears to be 
holding back on its  decision for the time being).16 
In January 2012, a conflict-of-interest scandal rocked the FDA when 
a pharmaceutical giant was allowed to keep its oral birth-control 
product on the US market, despite the FDA’s own reports of dozens 
of deaths caused by blood clots in women using the product.17 The 
FDA had appointed at least three scientists with financial ties to the 
pharmaceutical company to the product’s advisory committee, who 
voted in favour of the product. The FDA neglected to disclose their 
connections with the pharmaceutical company.17 Once again, the 
inclusion of a conflict-of-interest clause in the SAGCP is instrumental 
in dealing with this issue in South Africa.
Conclusion
The FDA’s reliance on the ethically less stringent ICH-GCP rather than 
the DoH may weaken the protection of research participants in many 
developing countries. This will depend on how well drug developers 
and clinical trial investigators will be able to abide by moral ethics, 
and how well they regulate themselves in terms of ethical conduct 
when conducting research in Third-world countries, especially where 
RECs are unable to uphold participant protection. 
In South Africa, research participants should be informed about 
these areas of concern in order to maintain awareness and 
emphasise the importance of a strong bio-ethical system. This 
could be done through public conferences, published articles, 
training methodologies for investigators and other research 
personnel, and discussion forums with leading and representative 
organisations and committees in the industry. 
Fortunately, in South Africa, the SAGCP goes a long way towards 
protecting research participants. It is imperative, however, that 
researchers in other developing countries are also made aware of 
these issues and advocate for stronger national ethico-guidelines.
References
1. Wolinsky H. The battle of Helsinki: Two troublesome paragraphs in the Declaration of 
Helsinki are causing a furore over medical research ethics. EMBO Rep 2006;7:670-672. 
[http//dx.doi.org/10.1038/sj.embor.7400743]
2. Food and Drug Administration, HHS. Human subject protection; foreign clinical 
studies not conducted under an investigational new drug application. Final rule. Fed 
Registr 2008;73(82):22800-22816. 
3. Kimmelman J, Weijer C, Meslin EM. Helsinki discords: FDA, ethics and international 
drug trials. Lancet 2009;373(9657):13-14. [http://dx.doi.org/10.1016/S0140-
6736(08)61936-4]
4. Williams J. Revising the Declaration of Helsinki. World Medical Journal 2008;54(4):120-
124. http://www.wma.net/en/30publications/20journal/pdf/wmj20.pdf (accessed 20 
September 2012).
5. World Medical Association. Declaration of Helsinki. Ferney-Voltaire: World Medical 
Association, 1964.
6. International Conference on Harmonization. International Conference on 
Harmonization Guideline for Good Clinical Practice (E6). Geneva: ICH, 1996. 
7. Moodley K, Myer L. Health research ethics committees in South Africa 12 years into 
democracy. BMC Med Ethics 2007;8:1. [http//dx.doi.org/10.1186/1472-6939-8-1]
8. Cleaton-Jones P, Wassenaar D. Issues in Research. Protection of human participants 
in health research – a comparison of some US federal regulations and South African 
research ethics guidelines. S Afr Med J 2010;100(11):712-716.
9. Moffett J. New Strategies in research ethics: Guidance for a global 
approach. Fam Health Int July 2009. http://www.fhi360.org/NR/rdonlyres/
efma2ljokjf57ewgcpmwy73cdl4vk35bmrrnlw4hj7qpai3dlj2m7cm4mboco 
cu6kasrakrdgnjxtd/Mera0907.pdf (accessed 8 May 2012).
10. Landes M. Can context justify an ethical double standard for clinical research in 
developing countries? Global Health 2005;1(1):11. [http://dx.doi.org/10.1186/1744-
8603-1-11]
11. Wikimedia Foundation, Inc. Declarationn of Helsinki. http://en.wikipedia.org/wiki/
Declaration_of_Helsinki (accessed 8 May 2012).
12. Levine RJ. New international ethical guidelines for research involving human 
subjects. Ann Int Med 1993;119(4):339-341. [http//dx.doi.org/10.2307/3528269].
13. SA Department of Health. Guidelines for Good Practice in the Conduct of Clinical 
Trials with Human Participants in South Africa. Pretoria: Government Printer, 2006.
14. National Health Act (Act No 61 of 2003). Government Gazette, RSA; Vol 469, No 
26595; 23 July 2004. http://www.info.gov.za/view/DownloadFileAction?id=68039 
(accessed 31 July 2012).
15. Huff EA. FDA Commissioner Margaret Hamburg pushing to eliminate conflict 
of interest laws, allow paid drug company shills to fill advisory positions. 
Naturalnews. com 18 August 2011. http://www.naturalnews.com/033361_FDA_
conflicts_of_interest.html (accessed 8 May 2012).
90     December 2012, Vol. 5, No. 2  SAJBL
Article
16. Philippidis A. FDA backtracks on conflict-of-interest rule changes for advisory panel 
members. Genetic Engineering and Biotechnology News 5 March 2012. http://www.
genengnews.com/insight-and-intelligenceand153/fda-backtracks-on-conflict-of-
interest-rule-changes-for-advisory-panel-members/77899566/ (accessed 11 May 
2012).
17. Malone P. Conflict of interest strikes again at the FDA. Jdsupra.com, 24 January 2012. 
http://www.jdsupra.com/post/documentViewer.aspx?fid=7918d12d-8afa-4617-
a264-f8bc6c8781d0 (accessed 9 May 2012).
Accepted 2 November 2012.
